Safety and Performance Evaluation of the Nephronyx System for the Treatment of Patients With ADHF

NCT ID: NCT05759806

Last Updated: 2025-05-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-19

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this interventional study is to evaluate the safety and functional performance of the Nephronyx System in patients with ADHF, presenting clinical signs of volume overload and compromised response to diuretics.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Decompensated Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ADHF patients

ADHF patients with compromised response to diuretics treated with Nephronyx system

Group Type EXPERIMENTAL

Nephronyx system (Perfuser)

Intervention Type DEVICE

Temporary deployment of the Nephronyx system (Perfuser)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nephronyx system (Perfuser)

Temporary deployment of the Nephronyx system (Perfuser)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

The Nephronyx system (Perfuser)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient admitted to the hospital with a primary diagnosis of ADHF
* Patient has signs of volume overload as evidence by a score of ≥ 4 on the EVEREST score
* Patient with Left Ventricular Ejection Fraction LVEF \>15%
* Patient has compromised response to diuretics
* NT-proBNP \>450 pg/mL if aged \<55 years, \>900 pg/mL if aged between 55 and 75 years and \>1800 pg/mL if aged \>75 years

Exclusion Criteria

* Patient with active DVT or history of DVT
* Patient has documented or evidence of Renal artery stenosis
* BMI\>35 Kg/m\^2
* Patient has documented, untreated symptomatic coronary artery disease (CAD) requiring revascularization
* Patient is in Cardiogenic shock
* Patient has blood dyscrasia, acute anemia, thrombocytopenia, bleeding diathesis, or coagulopathy
* Temperature \> 38°C, or sepsis, or active systemic infection requiring IV anti-microbial treatment
* Patient has shown liver cirrhosis or has signs of liver damage
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nephronyx LTD

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Doron Aronson, MD

Role: STUDY_DIRECTOR

Rambam Health Care Campus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rambam Medical Center

Haifa, , Israel

Site Status RECRUITING

Shaare Zedek Medical Center

Jerusalem, , Israel

Site Status RECRUITING

The Baruch Padeh Medical Center, Poriya

Poria Illit, , Israel

Site Status RECRUITING

Kaplan Medical Center

Rehovot, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sagy Karavany

Role: CONTACT

972-8-9999734

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Amir Solomonica, MD

Role: primary

Shemy Carasso, MD

Role: primary

+972-2-5645646

Wadi Kinany, MD

Role: primary

Sorel Goland, MD

Role: primary

+972-8-9440070

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLD-NPX-085

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.